Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279Silvana Leit, C. E. Masse, Wenyan Miao et al.|Journal of Medicinal Chemistry|2023Cited by 60
Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockadeDavid Ciccone, Christine Loh, Fu‐Shan Kuo et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 8
Discovery and characterization of novel inhibitors of CTP synthase 1 (CTPS1) for the treatment of autoimmune and inflammatory diseaseJoshua McElwee, Peter J. Tummino, Neelu Kaila et al.|The Journal of Immunology|2023Cited by 2
Abstract 1649: Mechanistic understanding of HPK1 inhibition on enhanced human T cell activation and tumor immunity in a syngeneic modelDavid Ciccone, Neelu Kaila, Vad Lazari et al.|Cancer Research|2021Cited by 1
Abstract 942: HPK1, hematopoietic progenitor kinase 1, is a promising therapeutic target for cancer immunotherapyDavid Ciccone, Neelu Kaila, Jennifer L. Rocnik et al.|Cancer Research|2020Cited by 1